The present study elucidates the previously unknown link between EIF5A2 and KLF4 and EIF5A2/pRb/E2F1/KLF4 axis is firstly confirmed which is a novel mechanism of the tumor initiation and chemo-resistance role of EIF5A2 and our results indicates that blocking this pathway may be a promising CSCs-specific therapeutic approach combined with platinum-based chemistry to treat EOC. This evidence concerns the gene KLF4 and neoplasm.